Skip to main content

Table 1 Comprehensive list of PD-L1 inhibitors along with FDA-approved disease treatment, clinical trials, and primary endpoints

From: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

PD-L1 inhibitors/company Disease Drug therapy Primary endpoints References
Atezolizumab (MPDL3280A), Roche Genentech NSCLC Atezolizumab vs docetaxel OS, 15.7 months vs 10.3 months [42]
NSq NSCLC Atezolizumab, carboplatin, paclitaxel, and bevacizumab vs atezolizumab; carboplatin and paclitaxel vs carboplatin, paclitaxel, and bevacizumab OS 19.2 months (4 drugs) vs 14.7 months (3 drugs) [43]
UC Atezolizumab vs chemotherapy OS 11.1 months vs 10.6 months [37, 38]
ES-SCLC Atezolizumab, carboplatin, and etoposide vs carboplatin and etoposide PFS 5.2 months vs 4.3 months; OS 12.3 months vs 10.3 months [44]
TNBC Atezolizumab plus nab-paclitaxel vs nab-paclitaxel PFS 7.5 months vs 5.0 months; OS 25.0 months vs 15.5 months [45]
Durvalumab (MEDI4736), AstraZeneca UC Durvalumab ORR 17.8% [59]
Unresectable stage III NSCLC Durvalumab vs placebo PFS 16.8 months vs 5.6 months [60]
Avelumab (MSB0010718C), Merck and Pfizer MCC Avelumab ORR 33% (11% complete and 22% partial) [69]
UC Avelumab ORR 16.1% at least 6 months [70, 71]
RCC Avelumab plus axitinib vs sunitinib PFS 13.8 months vs 8.4 months [79]
Envafolimab (KN035), Alphamab Oncology N/A N/A   [80, 81]
BMS-936559, Bristol-Myers Squibb N/A N/A   [82]
CK-301,Checkpoint Therapeutics N/A N/A   [83]
CS-1001, CStone Pharmaceuticals N/A N/A   [84]
SHR-1316 (HTI-1088), Hengrui Therapeutics N/A N/A   [85]
BGB-A333, BeiGene N/A N/A   [86]
  1. NSCLC non-small cell lung cancer, UC urothelial cancer, MCC Merkel cell carcinoma, TNBC triple-negative breast cancer, RCC renal cell carcinoma, ES-SCLC extensive-stage small cell carcinoma, NSq NSCLC non-squamous non-small cell lung cancer, MUC metastatic urothelial carcinoma, PFS progression free survival, OS overall survival, ORR objective response rate